PCI Pharma Services, a global leader in contract development and manufacturing (CDMO) for complex biopharma therapies, is investing over $365 million to expand its infrastructure for drug-device combination products using advanced drug delivery systems, with a focus on injectables. The investment includes new and expanded facilities in Europe and North America, driven by new business and aimed at supporting future growth.
These investments build on PCI’s 20+ years of biologics expertise, exemplified by its Biotech Center of Excellence in Philadelphia, which specializes in prefilled syringes, vial labeling, and autoinjector assembly. The company recently enhanced its capabilities at this facility with advanced automated drug delivery technologies, ensuring its leadership in innovation.
U.S. Expansion
PCI is planning a 545,000-square-foot expansion at its Rockford, Illinois campus to support drug delivery and drug-device combination packaging. The phased project includes 475,000 square feet for injectable packaging and warehousing, with over 20 customer suites. A further 70,000-square-foot expansion will cater to high-speed packaging for various drug delivery systems, including prefilled syringes, autoinjectors, and on-body injectors. Operations are set to begin in phases, with completion expected by Q3 2025.
European Expansion
In Europe, PCI is enhancing its operations with a new facility near Dublin, Ireland, focused on pharmaceutical packaging and device assembly, slated to begin operations in Q4 2024. Another facility in CityNorth Dublin, opening in Q3 2025, will handle injectable drug packaging and cold chain storage. Both facilities will offer advanced technology, cold chain storage, and scalable equipment to meet the growing needs of pharma and biopharma customers in the EU market.
These investments position PCI Pharma as a leader in the full lifecycle management of drug-device combination products, from development and clinical trials to commercialization. CEO Salim Haffar highlighted that this multi-continent expansion reflects PCI’s commitment to supporting life-changing therapies and meeting the evolving needs of the market.
